CA A Cancer Journal for Clinicians· 2020Q1
Cancer statistics, 2020
- 21,461citations
- Q1SCImago
- 2020year
Short summary
In 2020, the US is projected to see 1.8M new cancer cases and 606K deaths, with overall mortality down 29% since 1991 due to declines in major cancers, but progress has slowed for breast and colorectal cancers and halted for prostate cancer.
AI-generated from the title and abstract; the full text is not read.
Key points
- Projected 1.8M new cancer cases and 606K deaths in the US for 2020.
- Overall cancer death rate has declined 29% since 1991, saving an estimated 2.9M lives.
- Progress has slowed for female breast and colorectal cancers, and halted for prostate cancer.
- Lung cancer death rates have accelerated, contributing to a 2.2% drop in overall mortality from 2016-2017.
- Dramatic declines in melanoma mortality are linked to new therapies for metastatic disease.
AI-generated from the title and abstract; the full text is not read.
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
The authors' abstract, as published at the source. CA A Cancer Journal for Clinicians, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Economics and Econometrics
Economics and EconometricsEconomics, Econometrics and Finance